The veteran psilocybin PTSD pilot will be cited in ≥2 congressional statements/amendments but generate no FDA guidance response within 10 weeks.

A small government-funded pilot study giving psilocybin to veterans with PTSD (post-traumatic stress disorder) is likely to get mentioned in at least two speeches or proposed amendments in Congress. But the FDA (the US Food and Drug Administration, which decides what medical treatments are approved) almost certainly won't issue any formal response or new guidance because of it. A single small pilot study — especially one without a control group — doesn't carry enough scientific weight to make regulators act.

Advocacy value outstrips evidentiary weight; FDA does not respond to open-label pilots with formal action.